Stockscreener 앱 받기
49.69
0.49%
0.17
전일 마감가:
$49.86
열려 있는:
$50.33
하루 거래량:
48,730
Relative Volume:
0.04
시가총액:
$5.87B
수익:
$3.13M
순이익/손실:
$-545.28M
주가수익비율:
-9.0018
EPS:
-5.52
순현금흐름:
$-401.27M
1주 성능:
-8.40%
1개월 성능:
-6.89%
6개월 성능:
-16.69%
1년 성능:
+57.86%
1일 변동 폭
$49.53
$50.45
1주일 범위
$49.53
$55.14
52주 변동 폭
$30.68
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CYTK | 49.92 | 5.87B | 3.13M | -545.28M | -401.27M | -5.52 |
| VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - Yahoo Finance
Cytokinetics and Bayer ink deal for aficamten in Japan - The Pharma Letter
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Bayer acquires rights to Cytokinetics' heart drug in Japan - MSN
Royce & Associates LP Has $1.28 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics CEO Robert Blum sells shares for $252,750 - Investing.com
Cytokinetics CEO Robert Blum sells shares for $252,750 By Investing.com - Investing.com UK
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HC - GuruFocus.com
Cytokinetics, Bayer in Japan Licensing Pact for Aficamten - MarketWatch
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Yahoo Finance
First Turn Management LLC Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan - Yahoo Finance UK
Bayer: exclusive licensing agreement with Cytokinetics in Japan - Marketscreener.com
Bayer secures rights to heart drug in multi-million deal - Marketscreener.com
Cytokinetics Lands €50M Bayer Deal for HCM Drug Aficamten in Japan, €580M+ Potential | CYTK Stock News - StockTitan
H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - The Manila Times
Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com
Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells $370,880 in stock - Investing.com
Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat
FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com
Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan
Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference - Yahoo Finance
Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan
HC Wainwright Forecasts Reduced Earnings for Cytokinetics - MarketBeat
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com
Van ECK Associates Corp Has $3.80 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics started at outperform by RBC, valuation cited - MSN
Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign - MM+M Online
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript - Insider Monkey
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Cytokinetics: Q3 Earnings Snapshot - AOL
Cytokinetics director resigns, board reduced to eight By Investing.com - Investing.com UK
Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strate - GuruFocus.com
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Cytokinetics Inc earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Cytokinetics Reports Third Quarter 2024 Financial Results - The Manila Times
International Assets Investment Management LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024 - The Manila Times
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):